DMSO (with other agents)

Dimethyl sulfoxide, commonly known as DMSO, is a unique pharmaceutical agent widely used in equine medicine for its remarkable anti-inflammatory properties and exceptional ability to penetrate biological membranes. This colorless, odorless liquid derived from wood pulp has become an indispensable tool in treating acute swelling and inflammation in horses. DMSO is frequently combined with other therapeutic agents such as corticosteroids, NSAIDs, or antibiotics to enhance their delivery through the skin and into underlying tissues. The combination of DMSO with other agents represents one of the most versatile approaches to managing localized inflammation in equine patients.

The mechanism of action of DMSO involves multiple pathways that contribute to its therapeutic effects. As a potent free radical scavenger, DMSO neutralizes harmful reactive oxygen species that contribute to tissue damage and inflammation. It also inhibits the production of prostaglandins, similar to traditional NSAIDs, which reduces pain and swelling at the site of injury. Perhaps most importantly, DMSO has the unique ability to rapidly penetrate intact skin and carry other dissolved medications with it, making it an invaluable penetration enhancer for topical drug delivery. This transdermal capability allows therapeutic concentrations of combined medications to reach deep tissues that would otherwise be inaccessible to topical treatments.

DMSO is available in several formulations for equine use, including topical gels, liquids, and injectable solutions for intravenous administration. The topical formulations are most commonly used in combination with other anti-inflammatory agents and are applied directly to the affected area. Veterinary-grade DMSO typically comes in concentrations ranging from 70% to 90% for topical use. The liquid form can be applied using gauze or cotton, while gel formulations provide easier application and better adherence to the treatment area. Injectable DMSO is reserved for more severe conditions and must be administered by a veterinarian.

While DMSO has an established safety profile in horses when used appropriately, proper veterinary supervision is essential to ensure optimal outcomes and minimize potential adverse effects. The concentration of DMSO used, the medications combined with it, and the duration of treatment all require professional assessment based on the individual horse's condition. Horse owners should understand that DMSO's penetration-enhancing properties mean that any contaminants on the skin or in the DMSO preparation can also be carried into the body, making the use of medical-grade products and proper skin preparation critical. Following veterinary guidance regarding application technique, frequency, and treatment duration will maximize therapeutic benefit while maintaining safety.

The primary indication for DMSO in equine medicine is the treatment of acute swelling and inflammation associated with musculoskeletal injuries. Horses commonly experience soft tissue trauma, joint inflammation, and tendon injuries that result in significant swelling that can impede healing and cause pain. DMSO, particularly when combined with other anti-inflammatory agents, provides rapid reduction in edema and inflammation at the injury site. This makes it a first-line treatment for acute injuries in performance horses, where rapid resolution of swelling is critical for maintaining soundness and returning to work.

When used for acute soft tissue injuries, DMSO combined with corticosteroids or NSAIDs delivers anti-inflammatory medication directly to the affected tissues. Common applications include treatment of splints, bowed tendons, suspensory ligament injuries, and joint effusion. The ability of DMSO to carry medications through intact skin allows therapeutic concentrations to reach inflamed structures without the systemic exposure that would occur with oral or injectable medications. This localized delivery is particularly valuable in performance horses where systemic medications may have competition withdrawal implications or unwanted systemic effects.

DMSO is also employed as a secondary treatment for various inflammatory conditions where reducing local swelling provides symptomatic relief. These include cellulitis, lymphangitis, and post-surgical swelling. In cases of acute laminitis, DMSO may be applied topically to the coronary band or administered intravenously to reduce inflammation in the laminar tissues. Some veterinarians also use DMSO in combination with antibiotics for the treatment of localized infections, taking advantage of its ability to enhance antibiotic penetration into infected tissues.

Additional clinical applications include treatment of exercise-induced inflammation in athletic horses, management of chronic joint conditions where localized treatment is preferred, and reduction of swelling following injections or minor procedures. DMSO combinations are sometimes used to treat proud flesh (exuberant granulation tissue) when combined with appropriate wound care medications. The versatility of DMSO as a carrier for other therapeutic agents makes it applicable to numerous conditions where enhanced topical drug delivery would be beneficial.

Veterinarians select DMSO combinations based on several factors including the nature and location of the inflammation, the horse's competition schedule, and the specific therapeutic goals. DMSO offers advantages over purely systemic treatments when localized drug delivery is desired and when minimizing systemic drug exposure is important. However, it is not a substitute for appropriate systemic therapy when conditions warrant, and the decision to use DMSO should be made in consultation with a veterinarian who can assess the individual case and recommend the most appropriate treatment approach.

Dosing protocols for DMSO combinations in horses must be determined by a veterinarian based on the specific condition being treated, the concentration of DMSO used, and the other medications combined with it. Unlike oral medications where weight-based dosing calculations apply, topical DMSO application is generally based on the size of the affected area and the severity of inflammation rather than total body weight. However, the concentration of any added medications must still be carefully calculated, and the total amount applied should be limited to avoid excessive systemic absorption through the skin.

Typical topical application involves using a 70% to 90% DMSO solution or gel, often combined with a corticosteroid such as fluocinolone or a topical NSAID. The affected area should be clean and dry before application, as any contaminants on the skin can be carried into the tissues along with the medication. A thin layer is generally applied to the treatment area, covering the swollen or inflamed region. Application frequency typically ranges from once to twice daily, depending on the severity of the condition and the veterinarian's recommendations. Higher concentrations may be used for initial treatment of severe swelling, with lower concentrations for maintenance therapy.

Treatment duration varies considerably based on the condition being addressed. Acute injuries may require only a few days to a week of treatment, while chronic inflammatory conditions might necessitate longer-term application. The veterinarian will typically reassess the horse after the initial treatment period to determine whether continued therapy is needed, whether the concentration should be adjusted, or whether the treatment can be discontinued. Most practitioners recommend limiting continuous topical DMSO use to avoid potential skin irritation and other complications associated with prolonged application.

Proper application technique is essential for both efficacy and safety when using DMSO combinations. The person applying the medication should wear appropriate gloves, as DMSO will readily penetrate human skin and can carry any medications or contaminants into the handler's body as well. The horse's skin should be clean and free of dirt, liniments, or other products before application. DMSO should be applied using clean gauze, cotton, or gloved hands, spreading it evenly over the affected area. Some practitioners recommend wrapping the area after application to enhance absorption and protect the treatment site, while others prefer to leave it open. Following the specific application instructions provided by the veterinarian is critical.

If a dose is missed, the treatment should be applied as soon as it is remembered, unless it is almost time for the next scheduled application. In that case, the missed dose should be skipped and the regular schedule resumed. Doubling up on applications to make up for a missed dose is not recommended, as this could increase the risk of skin irritation or excessive systemic absorption. Maintaining a consistent application schedule helps optimize therapeutic outcomes and allows for accurate assessment of treatment response.

Completing the prescribed course of treatment is important even if the swelling appears to have resolved, as underlying inflammation may persist. However, treatment should not be extended beyond the veterinarian's recommendations without consultation, particularly when corticosteroids are included in the combination. Horse owners should contact their veterinarian if the condition worsens during treatment, if new symptoms develop, or if there is no improvement after the expected treatment period.

DMSO is generally well-tolerated in horses when used appropriately under veterinary supervision, though several side effects and considerations should be understood by horse owners. The most commonly observed effects are local reactions at the application site, which are typically mild and self-limiting. Understanding the potential side effects helps owners monitor their horses appropriately during treatment and know when veterinary consultation is needed.

The most frequently reported side effect of topical DMSO use is skin irritation at the application site. This may manifest as redness, dryness, or mild scaling of the skin, particularly with repeated applications or higher concentrations. Some horses may exhibit sensitivity to the application, showing signs of discomfort such as skin twitching or attempts to rub the treated area. These local reactions typically resolve after treatment is discontinued and the skin is allowed to recover. Using lower concentrations of DMSO or reducing application frequency often helps manage skin sensitivity while maintaining therapeutic benefit.

A distinctive and unavoidable effect of DMSO administration is the characteristic garlic or oyster-like odor that develops on the horse's breath within minutes of application, even when DMSO is applied topically. This occurs because DMSO is rapidly absorbed through the skin and distributed throughout the body, with metabolites being exhaled through the lungs. While not harmful, this odor can be quite strong and may persist for several hours after application. Some horses may also experience an unusual taste in their mouths, which can temporarily affect appetite. These effects are transient and resolve as the DMSO is metabolized and eliminated from the body.

More significant side effects, while uncommon with appropriate topical use, can occur and warrant veterinary attention. These include severe skin reactions such as blistering or chemical burns, which may occur with very high concentrations or if the skin has been damaged prior to application. Signs of systemic toxicity, though rare with topical use, may include lethargy, decreased appetite, or changes in urination. Horses receiving intravenous DMSO are at higher risk for systemic effects, including hemolysis (destruction of red blood cells) if administered too rapidly or at excessive concentrations.

Rare but serious adverse reactions that require immediate veterinary attention include severe allergic reactions, marked behavioral changes, signs of colic, or any indication of laminitis in horses receiving corticosteroid-containing DMSO combinations. Horse owners should also be aware that the penetration-enhancing properties of DMSO mean that any adverse effects from combined medications may be enhanced. If the horse develops any unexpected symptoms during DMSO treatment, the application should be stopped and the veterinarian contacted for guidance. Regular monitoring during treatment and prompt communication with the veterinarian about any concerns helps ensure safe and effective use of DMSO combinations.

DMSO use is contraindicated in horses with known hypersensitivity or previous adverse reactions to dimethyl sulfoxide or any components of the combination product being used. While true DMSO allergies are uncommon, horses that have experienced severe skin reactions, systemic symptoms, or other adverse effects following previous DMSO exposure should not receive the medication again. Additionally, horses with allergies to any of the other medications combined with DMSO, such as specific corticosteroids or NSAIDs, should not receive those combination products. Disclosing any history of medication reactions to the veterinarian is essential before initiating DMSO therapy.

Horses with pre-existing liver or kidney disease require careful evaluation before DMSO use, particularly for intravenous administration or extensive topical application that might result in significant systemic absorption. DMSO is metabolized by the liver and eliminated through the kidneys, and impaired organ function could lead to drug accumulation and increased risk of toxicity. While limited topical use in horses with mild organ dysfunction may be acceptable under veterinary supervision, horses with significant hepatic or renal impairment may need alternative treatment approaches. Blood work to assess organ function may be recommended before initiating treatment in horses with known or suspected organ disease.

DMSO should be used with extreme caution or avoided entirely in pregnant and lactating mares, as the drug readily crosses biological membranes and may affect the developing fetus or nursing foal. The safety of DMSO during pregnancy has not been definitively established in horses, and the potential for harm to the fetus must be weighed against the therapeutic benefits. When treatment is necessary in pregnant mares, veterinarians may recommend alternative therapies or use DMSO only when clearly needed and at the lowest effective concentration. Similarly, nursing mares should be treated with caution, as DMSO metabolites may appear in milk.

Additional contraindications relate to the specific circumstances of application. DMSO should not be applied to open wounds, damaged skin, or areas with active infection unless specifically directed by a veterinarian, as it can carry bacteria or other pathogens into deeper tissues. The penetration-enhancing properties that make DMSO therapeutically valuable also mean it can facilitate the entry of harmful substances. DMSO combinations containing corticosteroids should not be used in horses with active systemic infections, as immunosuppressive effects could worsen the infection. Horses with a history of laminitis or metabolic conditions such as equine metabolic syndrome or pituitary pars intermedia dysfunction require special caution with corticosteroid-containing DMSO products due to increased laminitis risk.

Understanding drug interactions is critical when using DMSO combinations, as the penetration-enhancing properties of DMSO can significantly alter the absorption and effects of other medications. When DMSO is combined with other topical agents, their absorption through the skin is dramatically increased, which can enhance therapeutic effects but also increase the risk of systemic side effects and toxicity. This fundamental property of DMSO means that any concurrent topical medication use must be carefully coordinated with veterinary guidance. Applying multiple topical products to the same area without veterinary direction could result in unintended drug interactions or excessive absorption.

Of particular concern is the concurrent use of DMSO-NSAID combinations with systemic NSAIDs. While DMSO itself is not classified as a traditional NSAID, topical DMSO products frequently contain NSAID medications, and significant systemic absorption can occur. Combining topical NSAID-containing DMSO products with oral or injectable NSAIDs such as phenylbutazone, flunixin meglumine, or firocoxib creates a dangerous NSAID stacking situation that can lead to severe gastrointestinal ulceration, right dorsal colitis, and renal damage. Horse owners must inform their veterinarian of all medications the horse is receiving, including any oral anti-inflammatories, before using DMSO combinations topically.

DMSO combinations containing corticosteroids require careful consideration of interactions with other medications and overall corticosteroid exposure. Concurrent use of topical corticosteroid-DMSO products with systemic corticosteroids increases the total corticosteroid load on the body, potentially leading to enhanced immunosuppressive effects and increased risk of laminitis. A washout period of at least 24 to 48 hours is generally recommended between NSAID and corticosteroid use, and this applies to topical DMSO combinations as well. Competition horses must be particularly aware that corticosteroids absorbed through DMSO-enhanced topical application can result in positive drug tests.

Competition and performance horses present special considerations for DMSO drug interactions related to regulatory compliance. DMSO itself is a prohibited substance under many competition rules, with specific detection times and withdrawal recommendations. When combined with other medications that are also regulated, the detection window for those substances may be affected by enhanced absorption. Horse owners competing under FEI, USEF, or racing commission rules must work closely with their veterinarian to understand withdrawal times and ensure compliance. Maintaining accurate treatment records is essential, and when in doubt about competition timing, consulting with a veterinarian familiar with current regulations is strongly recommended. The rules regarding DMSO and its combinations change periodically, so relying on current official guidance rather than historical information is important.

Appropriate monitoring during DMSO treatment helps ensure safety and allows for early detection of any adverse effects. Horse owners should observe the application site daily for signs of skin irritation, including redness, blistering, excessive dryness, or any breakdown of the skin surface. The horse's overall demeanor and appetite should be noted, as changes could indicate systemic absorption issues. While routine blood work is not typically required for short-term topical DMSO use, horses receiving extended treatment or those with pre-existing health conditions may benefit from periodic monitoring of liver and kidney function as recommended by their veterinarian.

Special populations of horses require additional precautions when considering DMSO therapy. Foals and young horses have different skin permeability and metabolic capabilities than adult horses, and DMSO absorption may be enhanced in these patients. Geriatric horses may have reduced organ function that affects drug metabolism and elimination. Pregnant and lactating mares, as previously discussed, should be treated with particular caution. Horses with chronic conditions such as pituitary pars intermedia dysfunction or equine metabolic syndrome are at increased risk of laminitis and require careful evaluation before using corticosteroid-containing DMSO combinations. These special populations benefit from veterinary assessment before initiating treatment.

Competition and performance horses require careful planning around DMSO use due to regulatory restrictions. DMSO is classified as a prohibited substance under FEI rules and most USEF disciplines, with specific detection times that vary based on the formulation used and the amount applied. Racing commissions also regulate DMSO use, and rules differ between jurisdictions. Horse owners must check current regulations from the relevant governing body before using DMSO on competition horses. The veterinarian can provide guidance on appropriate withdrawal times, but owners should verify this information independently against current official rules. Maintaining detailed treatment records, including dates, amounts, and formulations used, is essential for competition horses.

Safe handling of DMSO requires attention from the person administering the medication, not just for the horse's welfare but for human safety as well. DMSO readily penetrates human skin and will carry any dissolved substances into the handler's body. Always wear appropriate gloves when handling DMSO, and avoid contact with skin, eyes, and mucous membranes. If DMSO contacts human skin, wash the area thoroughly with soap and water immediately. Store DMSO products away from other chemicals and medications to prevent accidental contamination, as DMSO can dissolve and carry many substances through the skin.

Long-term or repeated use of DMSO combinations requires periodic reassessment by the veterinarian. Chronic use of topical corticosteroid-DMSO combinations can lead to skin atrophy, delayed wound healing, and increased susceptibility to local infections. Extended NSAID-containing combination use may contribute to the development of gastric ulcers or other NSAID-related complications. Regular veterinary evaluation helps determine whether continued treatment is appropriate, whether alternative therapies should be considered, or whether the treatment plan needs modification. Horse owners should not extend treatment beyond the prescribed duration without veterinary consultation.

Proper storage of DMSO products is essential for maintaining their stability and safety. DMSO should be stored at room temperature, typically between 59°F and 77°F (15°C to 25°C), away from extreme heat or cold. While DMSO has a relatively high freezing point of approximately 65°F (18°C) and may solidify in cooler conditions, this does not damage the product and it will return to liquid form when warmed to room temperature. However, repeated freeze-thaw cycles should be avoided as they may affect the stability of combination products containing other medications. Store DMSO in a location where temperature fluctuations are minimal, such as inside the barn office rather than an unheated tack room during winter months.

DMSO is photosensitive and should be protected from prolonged exposure to light, which can cause degradation of the product. Keep DMSO in its original container, which is typically designed to protect against light exposure, or in an opaque container if transferred. The storage area should be clean and dry, away from humidity that could affect product integrity. Importantly, DMSO should be stored separately from other chemicals, solvents, and medications because of its ability to absorb other substances. If DMSO becomes contaminated, those contaminants could be carried into the horse's tissues during application. Using a dedicated storage location helps prevent accidental contamination.

Safe handling practices are critical given DMSO's unique properties. The person applying DMSO should always wear impermeable gloves, as DMSO will penetrate latex gloves within minutes. Nitrile gloves provide better protection but should still be changed frequently during extended application sessions. Avoid touching the face, eyes, or any skin while handling DMSO, even while wearing gloves. If skin contact occurs, wash the area immediately with soap and water. Any gauze, cotton, or applicators used to apply DMSO should be disposed of properly rather than left where they might contact skin or other surfaces. Human exposure to DMSO can cause skin irritation, and any medications dissolved in the DMSO will be carried into the handler's system.

DMSO products should be checked for expiration dates before use, and expired products should be disposed of properly rather than used. Signs of product degradation include unusual color changes, separation of components in combination products, or unusual odors beyond the typical DMSO smell. Dispose of DMSO according to local regulations for pharmaceutical waste. Do not pour DMSO down drains or dispose of it with regular trash without checking local guidelines. Unused DMSO and contaminated application materials should be handled as pharmaceutical waste. Keeping products within their expiration dates and properly disposing of expired or contaminated materials helps ensure safe and effective treatment.

Draft breeds including Clydesdales, Percherons, Shires, and Belgians may require special consideration when using DMSO combinations due to their larger body mass and the extensive surface area that might require treatment. When treating large swollen areas on draft horses, the total amount of DMSO applied may be substantial, potentially leading to greater systemic absorption than would occur in lighter breeds with smaller treatment areas. Veterinarians may recommend limiting the treatment area or using lower concentrations in draft breeds to minimize systemic exposure. Additionally, the heavy feathering on the lower legs of many draft breeds can interfere with proper application and may trap moisture, potentially increasing skin irritation. Clipping feathering from treatment areas may be recommended for effective medication delivery.

Light horse breeds and warmbloods typically receive DMSO combinations without specific breed-related modifications, though individual variations in skin sensitivity may affect tolerance. Thoroughbreds, Arabians, and related breeds often have thinner, more sensitive skin that may be more prone to irritation from higher DMSO concentrations. Starting with lower concentrations and monitoring for skin reactions before increasing strength may be advisable in thin-skinned individuals. Warmbloods, particularly those with the WFFS gene, do not have specific concerns related to DMSO use in adult horses, though foals affected by this condition have extremely fragile skin and DMSO should be avoided.

Ponies and miniature horses require careful attention to the total amount of DMSO applied relative to their body size. While topical dosing is generally based on the treatment area rather than body weight, smaller equines have a higher surface area to body mass ratio, which can result in proportionally greater systemic absorption from topical applications. Using conservative amounts and monitoring closely for systemic effects is particularly important in these smaller patients. Ponies and miniatures are also more prone to equine metabolic syndrome and laminitis, making careful use of corticosteroid-containing DMSO combinations especially important in these breeds.

Certain breed-specific genetic conditions warrant consideration when planning DMSO therapy, particularly when combined with other medications. Quarter Horses and related breeds with HYPP may have altered responses to medications affecting electrolyte balance, though DMSO itself is not directly implicated. These horses should be monitored for any unusual muscle symptoms during treatment. Horses with PSSM may have altered metabolism that could theoretically affect drug handling, warranting standard veterinary monitoring. Appaloosas with equine recurrent uveitis may receive DMSO combinations for ocular inflammation under veterinary direction, with careful attention to the specific medications used. Friesians have increased sensitivity to certain medications and may be more prone to adverse reactions, suggesting conservative dosing and close monitoring. Overall, breed-specific conditions remind us of the importance of individualized veterinary assessment before initiating any treatment.

Within the topical anti-inflammatory category, several alternatives to DMSO combinations exist for treating localized swelling and inflammation in horses. Topical diclofenac preparations, marketed under brand names like Surpass, provide localized NSAID therapy without the penetration-enhancing properties of DMSO. These products may be preferred when DMSO-related side effects such as the characteristic odor or skin irritation are concerns. Topical corticosteroid preparations without DMSO provide anti-inflammatory effects but with less tissue penetration than DMSO combinations. Ice and cold therapy remain valuable non-pharmaceutical options for acute swelling, and poultices or sweats may provide symptomatic relief for certain conditions. The choice between these options depends on the specific condition, treatment goals, and individual horse factors.

Systemic anti-inflammatory medications offer an alternative approach when localized treatment is insufficient or impractical. Oral and injectable NSAIDs such as phenylbutazone, flunixin meglumine, and firocoxib provide systemic anti-inflammatory effects that address inflammation regardless of location. Systemic corticosteroids including dexamethasone and prednisolone may be indicated for more severe inflammatory conditions. These systemic options should not be combined with topical NSAID or corticosteroid DMSO combinations without veterinary direction due to the risk of enhanced toxicity from drug stacking. Veterinarians select between topical and systemic approaches based on the nature and extent of inflammation, competition status, and overall treatment strategy.

Complementary therapies can support DMSO treatment or serve as alternatives depending on the clinical situation. Physical therapies including therapeutic ultrasound, laser therapy, and shockwave treatment address inflammation through non-pharmaceutical mechanisms. Hydrotherapy and cold water spa treatments help manage swelling in the lower limbs. Supportive care measures such as appropriate bandaging, rest, and controlled exercise programs complement pharmaceutical treatment of musculoskeletal conditions. Nutraceutical supplements containing ingredients like omega-3 fatty acids, MSM, or herbal anti-inflammatories may provide supportive benefits, though they should not replace appropriate veterinary treatment for significant conditions. Any medication substitutions or additions should be discussed with the veterinarian to ensure safe and effective integration with the overall treatment plan.